Tranilast Sodium

• CAT Number: I000272
• CAS Number: 104931-56-8
• Molecular Formula: C18H16NNaO5
• Molecular Weight: 349.31
• Purity: ≥95%
• Synonyms: sodium;2-[3-(3,4-dimethoxyphenyl)prop-2-enoylamino]benzoate
• Target: Angiotensin Receptor
• Solubility: 10 mM in H2O
• Storage: Store at -20C
• IUPAC Name: sodium;2-[[(E)-3-(3,4-dimethoxyphenyl)prop-2-enoyl]amino]benzoate
• InChI: InChI=1S/C18H17NO5.Na/c1-23-15-9-7-12(11-16(15)24-2)8-10-17(20)19-14-6-4-3-5-13(14)18(21)22;/h3-11H,1-2H3,(H,19,20)(H,21,22);/q;+1/p-1/b10-8+
• InChIKey: KZGHWWBBHZLTTA-VRTOBVRTSA-M
• SMILES: COC1=C(C=C(C=C1)/C=C/C(=O)NC2=CC=CC=C2C(=O)[O-])OC.[Na+]

Tranilast Sodium（Cat No.:I000272）is an anti-inflammatory and anti-allergic drug that inhibits the release of chemical mediators like histamine and prostaglandins. It is used in the treatment of allergic conditions such as asthma, atopic dermatitis, and allergic conjunctivitis. Tranilast Sodium also prevents fibrosis by inhibiting the proliferation of fibroblasts and collagen production, making it valuable in managing hypertrophic scars and keloids. Its diverse pharmacological actions extend to potential applications in cardiovascular disease, where it may help prevent restenosis and improve outcomes in conditions involving excessive inflammation and tissue remodeling.

Reference

[1]. Rogosnitzky, M., R. Danks, and E. Kardash, Therapeutic potential of tranilast, an anti-allergy drug, in proliferative disorders. Anticancer Res, 2012. 32(7): p. 2471-8.

[2]. Swiderski, K., et al., Tranilast administration reduces fibrosis and improves fatigue resistance in muscles of mdx dystrophic mice. Fibrogenesis Tissue Repair, 2014. 7(1): p. 1.